Recherche clinique et fondamentale

Résumé synthétique les apports les plus importants des travaux des 4 dernières années avec leur impact clinique.

Le service d’urologie du CHRU de Lille (Pr VILLERS, Dr FANTONI, Dr COLIN, Dr FLAMAND, Dr MARCELLI, Dr RIGOT) est impliqué dans la recherche en :

- cancérologie (Pr VILLERS, Dr FANTONI, Dr COLIN, Dr FLAMAND)

- andrologie-infertilité (Dr MARCELLI, Dr RIGOT).

La recherche en cancérologie prostatique implique le plus de chercheurs et se fait au sein du service d’urologie, de l’Unité INSERM U 703 Thérapies interventionnelles assistées par l'image et la simulation de Serge MORDON et du service de radiologie du CHRU avec la collaboration avec les Pr LEMAITRE et Dr PUECH. Elle concerne le diagnostic par PSA, les biopsies couplées à l’imagerie par IRM et les traitements partiels ou traitement focal. Les études de traitement sont à la fois fondamentales, validant les lasers et à la fois cliniques, validant la sélection des patients dont le cancer peut-être traité partiellement et les modalités (lasers et ultrasons focalisés, robot chirurgical).

La recherche en cancérologie rénale, vésicale et testiculaire est aussi importante, impliquant le service d’urologie, d’imagerie, d’andrologie et de pathologie (Pr LEROY) du CHRU. Elle concerne la recherche sur les marqueurs tumoraux, l’imagerie et le pronostique. Les traitements partiels (robot chirurgical) et ablatifs (radio-fréquence) sont les implications cliniques.

La recherche en andrologie-infertilité est commune avec le laboratoire de spermiologie et d’imagerie du CHRU.

Des protocoles de recherche thérapeutique sont en cours au CHRU en Urologie.

Les publications des 4 dernières années concernent les articles suivants :

Publications Service d’Urologie Pr Arnauld VILLERS

02/2017

VillersA ; FlamandV ; ArquimedesR ; PuechP ; HaberGP ; Desai et al. , Robot-assisted Partial Prostatectomy for Anterior Cancer: a step-by-step guide., BJU Int., 2017,

RischmannP ; GeletA ; RicheB ; VillersA ; PasticierG ; Bondil et al. , Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate cancer: A Prospective Multicentric Hemiablation Study of 111 Patients., Eur. Urol., 2016,

HénonF ; Le NobinJ ; OuzzaneA ; VillersA ; StreckerG ; Bouyé et al. , [Factors influencing the choice of nondonor families in a French organ-harvesting center]., Prog. Urol., 2016, 26, 656-661

VickersA ; VertosickEA ; SjobergDD ; RoobolMJ ; HamdyF ; Neal et al. , Properties of the four kallikrein panel outside the diagnostic grey zone: meta-analysis of patients with positive digital rectal exam or prostate-specific antigen 10 ng / mL and above., J. Urol., 2016,

Villers, A ; Rubin, MA , Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy., Eur. Urol., 2016,

ScheltemaMJ ; TayKJ ; PostemaAW ; de BruinDM ; FellerJ ; Futterer et al. , Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project., World J Urol, 2016,

VillersA ; PuechP ; FlamandV ; HaberGP ; DesaiMM ; Crouzet et al. , Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional Outcomes., Eur. Urol., 2016,

ValerioM ; CerantolaY ; EggenerSE ; LeporH ; PolascikTJ ; Villers et al. , New and Established Technology in Focal Ablation of the Prostate: A Systematic Review., Eur. Urol., 2016,

ChenR ; SjobergDD ; HuangY ; XieL ; ZhouL ; He et al. , Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts: Data from the PBCG and CPCC., J. Urol., 2016,

Tay, KJ ; Villers, A ; Polascik, TJ , Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease., Curr Urol Rep, 2016, 17, 69

HeidenreichA ; ChowdhuryS ; KlotzL ; SiemensDR ; VillersA ; Ivanescu et al. , Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial., Eur. Urol., 2016,

CarlssonSV ; de CarvalhoTM ; RoobolMJ ; HugossonJ ; AuvinenA ; Kwiatkowski et al. , Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis., Cancer, 2016, 122, 3386-3393

Villers, A , Editorial Comment., J. Urol., 2016, 196, 1266-7

DurandM ; JainM ; RobinsonB ; AronowitzE ; El DouahyY ; Leung et al. , Magnetic Resonance Microscopy May Enable Distinction Between Normal Histomorphological Features and Prostate Cancer in the Resected Prostate Gland., BJU Int., 2016,

NyameYA ; ZargarH ; RamirezD ; GanesanV ; BabbarP ; Villers et al. , Robotic-assisted Laparoscopic Bilateral Nerve Sparing and Apex Preserving Cystoprostatectomy in Young Men With Bladder Cancer., Urology, 2016, 94, 259-64

PostemaAW ; De ReijkeTM ; UkimuraO ; Van den BosW ; AzzouziAR ; Barret et al. , Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project., World J Urol, 2016, 34, 1373-82

WalzJ ; EpsteinJI ; GanzerR ; GraefenM ; GuazzoniG ; Kaouk et al. , A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update., Eur. Urol., 2016, 70, 301-11

BruinsmaSM ; BangmaCH ; CarrollPR ; LeapmanMS ; RannikkoA ; Petrides et al. , Active surveillance for prostate cancer: a narrative review of clinical guidelines., Nat Rev Urol, 2016, 13, 151-67

ShoreND ; ChowdhuryS ; VillersA ; KlotzL ; SiemensDR ; Phung et al. , Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study., Lancet Oncol., 2016, 17, 153-63

2015

5-130

1. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ: Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design. Urol Oncol 2015

2. Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS: Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol 2015

3. Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, Villers A, Hugosson J, Moore CM: Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 2015; 67: 627-36

4. Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, Renard-Penna R, Salin A, Lebret T, Villers A, Soulie M, de la Taille A, Flamand V: Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. J Urol 2015; 194: 983-8

5. Pignot G, Mejean A, Bernhard JC, Bigot P, Timsit MO, Ferriere JM, Zerbib M, Villers A, Mouracade P, Lang H, Bensalah K, Couapel JP, Rigaud J, Salomon L, Bellec L, Soulie M, Vaessen C, Roupret M, Baumert H, Gimel P, Patard JJ, members C: The use of partial nephrectomy: results from a contemporary national prospective multicenter study. World J Urol 2015; 33: 33-40

6. Ouzzane A, Renard-Penna R, Marliere F, Mozer P, Olivier J, Barkatz J, Puech P, Villers A: Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies. J Urol 2015; 194: 350-6

7. Lebdai S, Villers A, Barret E, Nedelcu C, Bigot P, Azzouzi AR: Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad(R) Soluble focal treatment for localized prostate cancer. World J Urol 2015; 33: 965-71

8. Le Nobin J, Rosenkrantz AB, Villers A, Orczyk C, Deng FM, Melamed J, Mikheev A, Rusinek H, Taneja SS: Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. J Urol 2015; 194: 364-70

9. Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schroder FH, Roobol MJ, Hugosson J, de Koning HJ: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2015; 107: 366

10. Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A: Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol 2015

11. Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HU: Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol 2015; 67: 771-7

12. Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schroder FH, Zappa M: Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2015

13. Betrouni N, Makni N, Lakroum S, Mordon S, Villers A, Puech P: Computer-aided analysis of prostate multiparametric MR images: an unsupervised fusion-based approach. Int J Comput Assist Radiol Surg 2015; 10: 1515-26

14. Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, Villers A, Coleman J, Allen C, Scherz A, Emberton M: TOOKAD(R) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol 2015; 33: 945-53

2014

15. Zappa M, Puliti D, Hugosson J, Schroder FH, van Leeuwen PJ, Kranse R, Auvinen A, Carlsson S, Kwiatkowski M, Nelen V, Paez Borda A, Roobol MJ, Villers A: A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. Eur Urol 2014; 66: 401-3

16. Villers A: Words of wisdom. Re: Improving detection of clinically significant prostate cancer: MRI/TRUS fusion-guided prostate biopsy. Eur Urol 2014; 65: 1218-9

17. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC: Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 2014; 65: 1023-31

18. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-35

19. Puech P, Villers A, Ouzzane A, Lemaitre L: Prostate cancer: diagnosis, parametric imaging and standardized report. Diagn Interv Imaging 2014; 95: 743-52

20. Puech P, Ouzzane A, Gaillard V, Betrouni N, Renard B, Villers A, Lemaitre L: Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. Biomed Res Int 2014; 2014: 819360

21. Polascik TJ, Passoni NM, Villers A, Choyke PL: Modernizing the diagnostic and decision-making pathway for prostate cancer. Clin Cancer Res 2014; 20: 6254-7

22. Ploussard G, Staerman F, Pierrevelcin J, Larue S, Villers A, Ouzzane A, Bastide C, Gaschignard N, Buge F, Pfister C, Bonniol R, Rebillard X, Fadli S, Mottet N, Saint F, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Soulie M, Salomon L, Committee of Cancerology of the Association of French U: Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. World J Urol 2014; 32: 1331-8

23. Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulie M, Ferriere JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ: Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. Urol Oncol 2014; 32: 1024-30

24. Muller BG, van den Bos W, Brausi M, Cornud F, Gontero P, Kirkham A, Pinto PA, Polascik TJ, Rastinehad AR, de Reijke TM, de la Rosette JJ, Ukimura O, Villers A, Walz J, Wijkstra H, Marberger M: Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int 2014; 114: 698-707

25. Moore CM, Azzouzi AR, Barret E, Villers A, Muir GH, Barber NJ, Bott S, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M: Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU Int 2014

26. Marliere F, Puech P, Benkirane A, Villers A, Lemaitre L, Leroy X, Betrouni N, Ouzzane A: The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer. World J Urol 2014; 32: 951-8

27. Marien A, Gill I, Ukimura O, Betrouni N, Villers A: Target ablation--image-guided therapy in prostate cancer. Urol Oncol 2014; 32: 912-23

28. Kaouk JH, Haber GP, Autorino R, Crouzet S, Ouzzane A, Flamand V, Villers A: A novel robotic system for single-port urologic surgery: first clinical investigation. Eur Urol 2014; 66: 1033-43

29. Fiorio Pla A, Brossa A, Bernardini M, Genova T, Grolez G, Villers A, Leroy X, Prevarskaya N, Gkika D, Bussolati B: Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib. BMC Cancer 2014; 14: 939

30. Descotes F, Dessen P, Bringuier PP, Decaussin M, Martin PM, Adams M, Villers A, Lechevallier E, Rebillard X, Rodriguez-Lafrasse C, Devonec M, Paparel P, Perrin P, Lazar V, Ruffion A: Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages. BJU Int 2014; 113: 333-42

31. Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F: Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol 2014; 66: 655-63

32. Benkirane A, Khodari M, Yakoubi R, Lambert M, Koussa M, Ghoneim T, Haulon S, Villers A, Lemaitre L, Zini L: Polytetrafluoroethylene expanded prosthesis as replacement of the inferior vena cava in renal cell carcinoma with caval thrombus. Int J Urol 2014; 21: 448-52

33. Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schroder FH, Lilja H, Vickers AJ, Thompson IM: Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 2014; 32: 185-91

2013

34. Villers A, Ris L: Improved preparation and preservation of hippocampal mouse slices for a very stable and reproducible recording of long-term potentiation. J Vis Exp 2013

35. Villers A, Puech P: When and how should magnetic resonance imaging be used in evaluation of the patient with prostate cancer or increased prostate specific antigen? J Urol 2013; 190: 1641-2

36. Sufana Iancu A, Colin P, Puech P, Villers A, Ouzzane A, Fantoni JC, Leroy X, Lemaitre L: Significance of ADC value for detection and characterization of urothelial carcinoma of upper urinary tract using diffusion-weighted MRI. World J Urol 2013; 31: 13-9

37. Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mege-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L: Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology 2013; 268: 461-9

38. Ploussard G, Staerman F, Pierrevelcin J, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Villers A, Bastide C, Soulie M, Salomon L, Committee of Cancerology of the Association of French U: Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. J Urol 2013; 190: 1750-6

39. Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, Taneja SS, Emberton M: Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013; 63: 125-40

40. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, Consortium S: Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 2013; 64: 544-52

41. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Raj Persad Ch M, van der Meulen J, Villers A, Emberton M, Panel PC: Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urol Oncol 2013; 31: 281-4

42. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A, Tombal B, Villers A, Emberton M: Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging 2013; 37: 48-58

43. Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N: Focal therapy of prostate cancer: energies and procedures. Urol Oncol 2013; 31: 155-67

44. Bozzini G, Colin P, Betrouni N, Maurage CA, Leroy X, Simonin S, Martin-Schmitt C, Villers A, Mordon S: Efficiency of 5-ALA mediated photodynamic therapy on hypoxic prostate cancer: a preclinical study on the Dunning R3327-AT2 rat tumor model. Photodiagnosis Photodyn Ther 2013; 10: 296-303

45. Betrouni N, Colin P, Puech P, Villers A, Mordon S: An image guided treatment platform for prostate cancer photodynamic therapy. Conf Proc IEEE Eng Med Biol Soc 2013; 2013: 370-3

46. Barentsz J, Villers A, Schouten M: ESUR prostate MR guidelines. Author reply. Eur Radiol 2013; 23: 2322-3

47. Azzouzi AR, Barret E, Moore CM, Villers A, Allen C, Scherz A, Muir G, de Wildt M, Barber NJ, Lebdai S, Emberton M: TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 2013; 112: 766-74

17 Peer-reviewed articles from 2013 to 2016 in other journals :

128. Vandaele P, Marcelli F, Ouzzane A, Puech P, Villers A, Rigot JM: [Testicular nodules of infertile men and contrast enhanced ultrasonography: preliminary study]. Prog Urol 2015; 25: 274-81

129. Rizk J, Ouzzane A, Flamand V, Fantoni JC, Puech P, Leroy X, Villers A: [Long term biochemical recurrence free survival after radical prostatectomy for cancer: comparative analysis according to surgical approach and clinicopathological stage]. Prog Urol 2015; 25: 157-68

130. Puech P, Randazzo M, Ouzzane A, Gaillard V, Rastinehad A, Lemaitre L, Villers A: How are we going to train a generation of radiologists (and urologists) to read prostate MRI? Curr Opin Urol 2015

131. Ouzzane A, Helfrich O, Le Nobin J, Puech P, Betrouni N, Villers A: Understanding the pathological implications of MRI: application to focal therapy planning. Curr Opin Urol 2015; 25: 198-204

132. Manfredi M, Costa Moretti TB, Emberton M, Villers A, Valerio M: MRI/TRUS fusion software-based targeted biopsy: the new standard of care? Minerva Urol Nefrol 2015; 67: 233-46

133. Maillard F, Manouvrier S, Biardeau X, Ouzzane A, Villers A: [Lynch syndrome and risk of prostate cancer; review of the literature]. Prog Urol 2015; 25: 225-32

134. Helfrich O, Crouzet S, Ruffion A, Houlgatte A, Cavillon C, Gerard C, Villers A: [Evolution of the number of incident cases of prostate cancer in France from 2001 to 2012 from 5 hospital centers]. Prog Urol 2015; 25: 147-56

135. Ouzzane A, Puech P, Villers A: How accurately can MRI detect indolent disease? Curr Opin Urol 2014; 24: 264-9

136. Le Nobin J, Pruvot FR, Villers A, Flamand V, Bouye S: [Family refusal of organ donation: a retrospective study in a French organ procurement center]. Prog Urol 2014; 24: 282-7

137. Gnemmi V, Bouillez A, Gaudelot K, Hemon B, Ringot B, Pottier N, Glowacki F, Villers A, Vindrieux D, Cauffiez C, Van Seuningen I, Bernard D, Leroy X, Aubert S, Perrais M: MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/beta-catenin pathway and interaction with SNAIL promoter. Cancer Lett 2014; 346: 225-36

138. Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Molinie V, Ravery V, Rebillard X, Richaud P, Villers A, Soulie M, Les membres du C: [CCAFU Recommendations 2013: Prostate cancer]. Prog Urol 2013; 23 Suppl 2: S69-101

139. Rizk J, Villers A, Rigot JM, Marcelli F: [Erectile dysfunction: cardiovascular risk procedure]. Rev Prat 2013; 63: 241-3

140. Rebillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, Irani J, Lebret T, Rigaud J, Pfister C, Patard JJ, Richaud P, Salomon L, Coloby P, Soulie M, Les membres du C: [Incidence and mortality of urological cancers in 2012 in France]. Prog Urol 2013; 23 Suppl 2: S57-65

141. Peugniez C, Ghoneim T, Leroy X, Amela E, Fantoni JC, Culine S, Villers A, Adenis A: [Urachal cancers]. Bull Cancer 2013; 100: 509-17

142. Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T: [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results]. Prog Urol 2013; 23 Suppl 1: S34-43

143. Gnemmi V, Leroy X, Triboulet JP, Pruvot FR, Villers A, Leteurtre E, Buob D: Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas. Anal Quant Cytopathol Histpathol 2013; 35: 157-62

144. Bozzini G, Colin P, Betrouni N, Ouzzane A, Puech P, Villers A: [The outbreak of focal therapy for localized prostate cancer management]. Rev Prat 2013; 63: 489-93

145. Audenet F, Murez T, Ripert T, Villers A, Neuzillet Y: [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway]. Prog Urol 2013; 23 Suppl 1: S9-15

10,69,89,125,131-207